BidaskClub upgraded shares of Allergan PLC. (NYSE:AGN) from a sell rating to a hold rating in a research note issued to investors on Saturday.
A number of other research analysts have also recently weighed in on AGN. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the company a buy rating in a report on Monday, June 12th. ValuEngine cut Allergan PLC. from a buy rating to a hold rating in a report on Friday, June 2nd. Mizuho reduced their target price on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a report on Friday, June 9th. Cantor Fitzgerald began coverage on Allergan PLC. in a research note on Friday. They set a neutral rating and a $231.00 price objective on the stock. Finally, Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the stock a buy rating in a research note on Thursday, June 8th. Eight analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Allergan PLC. has an average rating of Buy and an average target price of $272.13.
Allergan PLC. (NYSE AGN) traded up 0.31% during trading on Friday, reaching $235.49. The company had a trading volume of 2,228,743 shares. The firm’s 50 day moving average is $230.75 and its 200-day moving average is $226.62. The company has a market capitalization of $79.09 billion, a P/E ratio of 7.34 and a beta of 1.16. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $261.27.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm had revenue of $3.57 billion for the quarter, compared to analysts’ expectations of $3.53 billion. During the same quarter last year, the firm earned $3.04 earnings per share. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. On average, equities analysts expect that Allergan PLC. will post $16.08 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by WKRB News and is the property of of WKRB News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.wkrb13.com/markets/2230858/allergan-plc-agn-upgraded-at-bidaskclub.html.
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date was Tuesday, May 16th. Allergan PLC.’s payout ratio is 9.63%.
In related news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Appaloosa LP raised its stake in shares of Allergan PLC. by 249.8% in the fourth quarter. Appaloosa LP now owns 4,261,406 shares of the company’s stock valued at $894,938,000 after buying an additional 3,043,097 shares in the last quarter. Janus Capital Management LLC raised its stake in shares of Allergan PLC. by 20.5% in the fourth quarter. Janus Capital Management LLC now owns 3,897,873 shares of the company’s stock valued at $818,699,000 after buying an additional 663,390 shares in the last quarter. Baupost Group LLC MA raised its stake in shares of Allergan PLC. by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock valued at $720,881,000 after buying an additional 1,430,625 shares in the last quarter. Norges Bank purchased a new stake in shares of Allergan PLC. during the fourth quarter valued at $682,333,000. Finally, Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. during the first quarter valued at $761,339,000. 84.88% of the stock is owned by hedge funds and other institutional investors.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230858/allergan-plc-agn-upgraded-at-bidaskclub.html
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.